Amgen Inc (AMGN)

165.67
NASDAQ : Health Care
Prev Close 164.19
Day Low/High 164.00 / 166.33
52 Wk Low/High 130.09 / 181.81
Avg Volume 2.81M
Exchange NASDAQ
Shares Outstanding 751.22M
Market Cap 123.34B
EPS 9.20
P/E Ratio 15.25
Div & Yield 4.00 (2.40%)

Latest News

Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA

Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA

Based on Phase 3 FRAME Study in Postmenopausal Women With Osteoporosis

Market Is Now Flat as a Pancake

If you want to know what an overbought market looks like, this is it.

Amgen (AMGN) Stock Rises on 'Non-Inferior' Late-Stage Trial Results

Amgen (AMGN) Stock Rises on 'Non-Inferior' Late-Stage Trial Results

A late-stage trial for Amgen’s (AMGN) drug ABP 980 shows its ‘non-inferiority’ to Roche’s (RHHBY) biosimilar branded product.

Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan

Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan

Exclusive Agreement Includes Nine Biosimilars

3 Drugs Stocks Dragging The Industry Down

3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the health services industry lower today.

Biotechs and Builders Will Rock 2Q Earnings

Biotechs and Builders Will Rock 2Q Earnings

A look at who will be up and who will down this earnings season.

Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab

Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab

First Amgen Biosimilar Candidate and Adalimumab Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

Repatha® (evolocumab) Pushtronex™ System Available to U.S. Patients in Early August

X(encor) Marks the Spot For Potential Gains

X(encor) Marks the Spot For Potential Gains

You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.

Goldman Sachs Recommends These 14 Conviction Buy Stocks for the Rest of 2016

Goldman Sachs Recommends These 14 Conviction Buy Stocks for the Rest of 2016

Goldman Sachs expects "rising uncertainty" in the second half of 2016 and suggests that investors stick to stocks within defensive sectors including consumer, health care and telecom services.

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

The company's shares were up nearly 2% in after hours trading.

Amgen's Struggle Means It's Time to Play 'D'

Traders and investors should either stand aside or start probing the short side.

European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients

European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients

Head-to-Head Phase 3 Trial Demonstrated Superiority of Kyprolis and Dexamethasone Over Velcade® (Bortezomib) and Dexamethasone in Patients with Relapsed Multiple Myeloma

Trade-Ideas: Amgen (AMGN) Is Today's

Trade-Ideas: Amgen (AMGN) Is Today's "Storm The Castle" Stock

Trade-Ideas LLC identified Amgen (AMGN) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

How Pfizer, Merck May Feel Long-Term Pinch From Brexit

How Pfizer, Merck May Feel Long-Term Pinch From Brexit

The eventual negative implications of Brexit could be greater for health care companies that have sizable exposure to Europe.

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

The Brexit-related market pullback has created stock-buying opportunities. Here are 14 more stocks for investors to consider from Morgan Stanley.

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

The U.S. woke up today to the news of a "Brexit" win, which has sent global markets reeling.

Why Biotechnology Goliath Amgen Is a Solid Long-Term Investment

Why Biotechnology Goliath Amgen Is a Solid Long-Term Investment

Shares of Amgen (AMGN) present investors with an opportunity for strong long-term returns.

Amgen Sponsors QB3@953 Incubator For Life Science Startups

Amgen Sponsors QB3@953 Incubator For Life Science Startups

Amgen Golden Ticket Winners Receive Lab Space and Other Benefits at QB3@953

Amgen Poised For Another Steep Drop

Amgen Poised For Another Steep Drop

Shares of Amgen could be facing a deep selloff.

3 Finds in Biotech's 'Pocket of Value'

Large biotech stocks are still at their cheapest valuations since 2011.

Amgen Is Looking Vulnerable to a Deep Selloff

Amgen Is Looking Vulnerable to a Deep Selloff

Amgen's drop on Friday has put the stock in a vulnerable position.